MTVAMETAVIA INC.
Is Metavia struggling financially?
Yes, by its own account. Metavia told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $9.6M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
8months
If the burn speeds up
Empty by Mar 2027
-
12months
If it eases off
Empty by Jun 2027
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$12.6M
÷
Cash burned over the last 12 months
$15.7M
What Metavia told the SEC
…trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements. We plan to continue to fund our operations through equity offerings, debt financing, the…
METAVIA INC., Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Cash burn is narrowing It is spending 58% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- TLPH Talphera $61.8M
- NXGL NexGel $3.2M
- VERU Veru $45.0M
- EXOZ Exozymes $66.4M
- ATOS Atossa Therapeutics $25.3M
- SPAI Safe Pro Group $109.3M